<?xml version='1.0' encoding='utf-8'?>
<document id="23360419"><sentence text="Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers."><entity charOffset="70-80" id="DDI-PubMed.23360419.s1.e0" text="lacosamide" /><entity charOffset="108-122" id="DDI-PubMed.23360419.s1.e1" text="levonorgestrel" /><entity charOffset="128-144" id="DDI-PubMed.23360419.s1.e2" text="ethinylestradiol" /><pair ddi="false" e1="DDI-PubMed.23360419.s1.e0" e2="DDI-PubMed.23360419.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23360419.s1.e0" e2="DDI-PubMed.23360419.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23360419.s1.e0" e2="DDI-PubMed.23360419.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23360419.s1.e1" e2="DDI-PubMed.23360419.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23360419.s1.e1" e2="DDI-PubMed.23360419.s1.e2" /></sentence><sentence text="To determine whether the antiepileptic drug lacosamide affects the pharmacokinetics or pharmacodynamics of a combined oral contraceptive (OC; ethinylestradiol 0"><entity charOffset="44-54" id="DDI-PubMed.23360419.s2.e0" text="lacosamide" /><entity charOffset="142-158" id="DDI-PubMed.23360419.s2.e1" text="ethinylestradiol" /><pair ddi="false" e1="DDI-PubMed.23360419.s2.e0" e2="DDI-PubMed.23360419.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23360419.s2.e0" e2="DDI-PubMed.23360419.s2.e1" /></sentence><sentence text="03 mg plus levonorgestrel 0"><entity charOffset="11-25" id="DDI-PubMed.23360419.s3.e0" text="levonorgestrel" /></sentence><sentence text="15 mg)" /><sentence text="" /><sentence text="This was an open-label trial in healthy female volunteers" /><sentence text=" Eligible women entered cycle 1 of the trial on the first day of menstruation" /><sentence text=" Cycle 1 was a medication-free, run-in phase of approximately 28 days to confirm that normal ovulation occurred" /><sentence text=" Volunteers with confirmed ovulation entered the subsequent cycle and started taking OCs" /><sentence text=" After establishing ovulation suppression (defined as progesterone serum concentration &lt;5"><entity charOffset="54-66" id="DDI-PubMed.23360419.s10.e0" text="progesterone" /></sentence><sentence text="1 nm on day 21 of the menstrual cycle) in volunteers taking the OCs in cycle 2, lacosamide 400 mg/day was administered concomitantly in the subsequent cycle (cycle 3)" /><sentence text=" The pharmacokinetic parameters of area under the concentration-time curve (AUC), maximum steady-state plasma drug concentration (Cmax ), and time to maximum concentration (tmax ) were measured for the OC components and lacosamide"><entity charOffset="220-230" id="DDI-PubMed.23360419.s12.e0" text="lacosamide" /></sentence><sentence text="" /><sentence text="A total of 37 volunteers completed cycle 1, and 32 completed cycle 2" /><sentence text=" In each of the 31 volunteers who completed the trial (through cycle 3), pharmacodynamic assessment showed progesterone serum concentration was &lt;5"><entity charOffset="107-119" id="DDI-PubMed.23360419.s15.e0" text="progesterone" /></sentence><sentence text="1 nm on day 21 of cycle 2, when the OC was administered alone, and on day 21 of cycle 3, when lacosamide was administered concomitantly"><entity charOffset="94-104" id="DDI-PubMed.23360419.s16.e0" text="lacosamide" /></sentence><sentence text=" The AUC of ethinylestradiol alone versus together with lacosamide was 1,067 ± 404 versus 1,173 ± 330 pg h/ml"><entity charOffset="12-28" id="DDI-PubMed.23360419.s17.e0" text="ethinylestradiol" /><entity charOffset="56-66" id="DDI-PubMed.23360419.s17.e1" text="lacosamide" /><pair ddi="false" e1="DDI-PubMed.23360419.s17.e0" e2="DDI-PubMed.23360419.s17.e0" /><pair ddi="false" e1="DDI-PubMed.23360419.s17.e0" e2="DDI-PubMed.23360419.s17.e1" /></sentence><sentence text=" Corresponding values of Cmax were 116" /><sentence text="9 ± 48" /><sentence text="8 versus 135" /><sentence text="7 ± 28" /><sentence text="6 pg/ml" /><sentence text=" For levonorgestrel, the AUC alone was 74"><entity charOffset="5-19" id="DDI-PubMed.23360419.s23.e0" text="levonorgestrel" /></sentence><sentence text="2 ± 21" /><sentence text="4 versus 80" /><sentence text="9 ± 18" /><sentence text="5 ng h/ml with lacosamide"><entity charOffset="15-25" id="DDI-PubMed.23360419.s27.e0" text="lacosamide" /></sentence><sentence text=" Corresponding values of Cmax were 6" /><sentence text="7 ± 1" /><sentence text="9 versus 7" /><sentence text="4 ± 1" /><sentence text="5 ng/ml" /><sentence text=" The AUC and Cmax point estimates and almost all 90% confidence intervals (except for Cmax of ethinylestradiol) for ethinylestradiol and levonorgestrel (with and without lacosamide) were within the conventional bioequivalence range, and no relevant changes in tmax were observed for ethinylestradiol (1"><entity charOffset="94-110" id="DDI-PubMed.23360419.s33.e0" text="ethinylestradiol" /><entity charOffset="116-132" id="DDI-PubMed.23360419.s33.e1" text="ethinylestradiol" /><entity charOffset="137-151" id="DDI-PubMed.23360419.s33.e2" text="levonorgestrel" /><entity charOffset="170-180" id="DDI-PubMed.23360419.s33.e3" text="lacosamide" /><entity charOffset="283-299" id="DDI-PubMed.23360419.s33.e4" text="ethinylestradiol" /><pair ddi="false" e1="DDI-PubMed.23360419.s33.e0" e2="DDI-PubMed.23360419.s33.e0" /><pair ddi="false" e1="DDI-PubMed.23360419.s33.e0" e2="DDI-PubMed.23360419.s33.e1" /><pair ddi="false" e1="DDI-PubMed.23360419.s33.e0" e2="DDI-PubMed.23360419.s33.e2" /><pair ddi="false" e1="DDI-PubMed.23360419.s33.e0" e2="DDI-PubMed.23360419.s33.e3" /><pair ddi="false" e1="DDI-PubMed.23360419.s33.e0" e2="DDI-PubMed.23360419.s33.e4" /><pair ddi="false" e1="DDI-PubMed.23360419.s33.e1" e2="DDI-PubMed.23360419.s33.e1" /><pair ddi="false" e1="DDI-PubMed.23360419.s33.e1" e2="DDI-PubMed.23360419.s33.e2" /><pair ddi="false" e1="DDI-PubMed.23360419.s33.e1" e2="DDI-PubMed.23360419.s33.e3" /><pair ddi="false" e1="DDI-PubMed.23360419.s33.e1" e2="DDI-PubMed.23360419.s33.e4" /><pair ddi="false" e1="DDI-PubMed.23360419.s33.e2" e2="DDI-PubMed.23360419.s33.e2" /><pair ddi="false" e1="DDI-PubMed.23360419.s33.e2" e2="DDI-PubMed.23360419.s33.e3" /><pair ddi="false" e1="DDI-PubMed.23360419.s33.e2" e2="DDI-PubMed.23360419.s33.e4" /><pair ddi="false" e1="DDI-PubMed.23360419.s33.e3" e2="DDI-PubMed.23360419.s33.e3" /><pair ddi="false" e1="DDI-PubMed.23360419.s33.e3" e2="DDI-PubMed.23360419.s33.e4" /></sentence><sentence text="5 ± 0" /><sentence text="6 h alone vs" /><sentence text=" 1" /><sentence text="4 ± 0" /><sentence text="7 h with lacosamide) or for levonorgestrel (1"><entity charOffset="9-19" id="DDI-PubMed.23360419.s38.e0" text="lacosamide" /><entity charOffset="28-42" id="DDI-PubMed.23360419.s38.e1" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.23360419.s38.e0" e2="DDI-PubMed.23360419.s38.e0" /><pair ddi="false" e1="DDI-PubMed.23360419.s38.e0" e2="DDI-PubMed.23360419.s38.e1" /></sentence><sentence text="5 ± 1" /><sentence text="0 h alone vs" /><sentence text=" 1" /><sentence text="1 ± 0" /><sentence text="6 h with lacosamide)"><entity charOffset="9-19" id="DDI-PubMed.23360419.s43.e0" text="lacosamide" /></sentence><sentence text=" Lacosamide pharmacokinetics were consistent with those observed in previous studies of lacosamide alone, with values for AUC of 113"><entity charOffset="1-11" id="DDI-PubMed.23360419.s44.e0" text="Lacosamide" /><entity charOffset="88-98" id="DDI-PubMed.23360419.s44.e1" text="lacosamide" /><pair ddi="false" e1="DDI-PubMed.23360419.s44.e0" e2="DDI-PubMed.23360419.s44.e0" /><pair ddi="false" e1="DDI-PubMed.23360419.s44.e0" e2="DDI-PubMed.23360419.s44.e1" /></sentence><sentence text="5 ± 20" /><sentence text="7 μg h/ml, Cmax of 13" /><sentence text="8 ± 2" /><sentence text="2 μg/ml, and tmax of 1" /><sentence text="1 ± 0" /><sentence text="4 h" /><sentence text="" /><sentence text="Lacosamide and an OC containing ethinylestradiol and levonorgestrel have low potential for drug-drug interaction; therefore, coadministration of the two drugs is unlikely to result in contraceptive failure or loss of seizure control"><entity charOffset="0-10" id="DDI-PubMed.23360419.s52.e0" text="Lacosamide" /><entity charOffset="32-48" id="DDI-PubMed.23360419.s52.e1" text="ethinylestradiol" /><entity charOffset="53-67" id="DDI-PubMed.23360419.s52.e2" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.23360419.s52.e0" e2="DDI-PubMed.23360419.s52.e0" /><pair ddi="false" e1="DDI-PubMed.23360419.s52.e0" e2="DDI-PubMed.23360419.s52.e1" /><pair ddi="false" e1="DDI-PubMed.23360419.s52.e0" e2="DDI-PubMed.23360419.s52.e2" /><pair ddi="false" e1="DDI-PubMed.23360419.s52.e1" e2="DDI-PubMed.23360419.s52.e1" /><pair ddi="false" e1="DDI-PubMed.23360419.s52.e1" e2="DDI-PubMed.23360419.s52.e2" /></sentence><sentence text="" /></document>